Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
-
Published:2024-08
Issue:8
Volume:24
Page:531-536.e1
-
ISSN:2152-2650
-
Container-title:Clinical Lymphoma Myeloma and Leukemia
-
language:en
-
Short-container-title:Clinical Lymphoma Myeloma and Leukemia
Author:
Matsunaga NaohiroORCID, Suzuki TomotakaORCID, Nishitarumizu Nozomi, Nakanishi Yoko, Kondo Aki, Kato Yukiyasu, Ebina Toru, Marumo Yoshiaki, Nakamura Tomoyuki, Nakashima Takahiro, Kinoshita Shiori, Narita Tomoko, Ri Masaki, Kusumoto Shigeru, Komatsu Hirokazu, Iida Shinsuke
Reference27 articles.
1. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma;Mateos;N Engl J Med,2018 2. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos;N Engl J Med,2016 3. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial;Moreau;Lancet,2021 4. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study;Attal;Lancet,2019 5. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma;Nahi;PLoS One,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|